- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.08. | BIOADAPTIVES, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.08. | BIOADAPTIVES, INC. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 13.08. | BioAdaptives, Inc. Announces CEO's Share Cancellation and Provides Capital Restructure Update | 307 | ACCESS Newswire | Company outlines adjustments to public float, lender lock-up and leak-out agreements, and growth-funding structure. LAS VEGAS, NV / ACCESS Newswire / August 13, 2026 / BioAdaptives, Inc. (OTCID:BDPT)... ► Artikel lesen | |
| 12.08. | BioAdaptives, Inc.: BioAdaptives Inc. Introduces XcellaraHeart: the World's First Stem Cell Mobilizer with a Targeted Cardiac Homing Signal | 287 | ACCESS Newswire | The flagship product of the new Xcellara cellular wellness platform is backed by a randomized, double-blind, placebo-controlled human clinical trial that showed an average increase of 268.8% in circulating... ► Artikel lesen | |
| 04.08. | BioAdaptiveas, Inc.: BioAdaptives Explains the Scientific Basis of the Dual-Action Xcellara "Supply and Direction" Platform | 253 | ACCESS Newswire | The Platform integrates clinically researched stem and progenitor cell mobilization with ingredients that have been studied for their roles in tissue signaling pathways. LAS VEGAS, NV / ACCESS Newswire... ► Artikel lesen | |
| BIOADAPTIVES Aktie jetzt für 0€ handeln | |||||
| 03.08. | BioAdaptives, Inc.: BioAdaptives Inc. Opens Commercial Ordering Window for XcellaraHeart Cellular Wellness Formula | 258 | ACCESS Newswire | Retirement of Largest Outstanding Convertible Debt Clears Runway for High-Growth E-Commerce Rollout of a Targeted Stem Cell Platform LAS VEGAS, NV / ACCESS Newswire / August 3, 2026 / BioAdaptives,... ► Artikel lesen | |
| 30.07. | BioAdaptives, Inc.: BioAdaptives Inc. Eliminates Major Market Overhang by Retiring the Debt of the Largest Convertible Commercial Investor | 671 | ACCESS Newswire | Strategic transaction alleviates dilutive pressure, showcasing financial strength and aligning shareholder value prior to product launches. LAS VEGAS, NV / ACCESS Newswire / July 30, 2026 / BioAdaptives... ► Artikel lesen | |
| 29.07. | BioAdaptives, Inc.: BioAdaptives Inc. Reports Scaling of E-Commerce Footprint and Consumer Reach for MyndSystem Nootropic Platform | 876 | ACCESS Newswire | LAS VEGAS, NV / ACCESS Newswire / July 29, 2026 / BioAdaptives, Inc. (OTCID:BDPT), a developer of natural, science-backed wellness solutions, today announced a significant expansion of its digital storefront... ► Artikel lesen | |
| 23.07. | BioAdaptives Inc. Announces Operational Readiness and Completion of the Commercial Supply Chain for Upcoming Product Launches | 213 | GlobeNewswire (Europe) | LAS VEGAS, July 23, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT), a developer of science-driven wellness products, today announces the successful completion of its commercial... ► Artikel lesen | |
| 16.07. | BioAdaptives Inc.: BioAdaptives Outlines Xcellara Platform Strategy: Integrating Stem Cell Supply and Direction for Targeted Wellness | 202 | GlobeNewswire (Europe) | LAS VEGAS, July 16, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives® Inc. (OTC: BDPT) today outlined the scientific strategy behind its Xcellara cellular wellness platform ahead of the August 1,... ► Artikel lesen | |
| 15.07. | BioAdaptives Inc.: BioAdaptives Inc. Announces XcellaraHeart, a Cardiovascular Wellness Formula Built on Xcellara's Human-Clinical Data Demonstrating a 268.8% Increase in Circulating Stem/Progenitor-Type Cells | 176 | GlobeNewswire (Europe) | LAS VEGAS, July 15, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives® Inc. (OTC: BDPT), developer of the Xcellara line of stem cell mobilization supplements, today announced the upcoming commercial... ► Artikel lesen | |
| 25.06. | BioAdaptives Inc.: BioAdaptives Completes MyndSystem Platform with TruShield Certification of MyndRenew, Securing Full WADA Compliance for Professional Athletes and Expanding Market Opportunity | 418 | GlobeNewswire (Europe) | LAS VEGAS, June 25, 2026 (GLOBE NEWSWIRE) -- via IBN - BioAdaptives, Inc. (OTC: BDPT), the parent company of MyndSystem, today announced that its nighttime repair formula, MyndRenew, has received... ► Artikel lesen | |
| 20.05. | BioAdaptives Inc.: BioAdaptives Launches MyndSystem Website - The First Supplement Platform Designed to Support Both Daytime Cognitive Performance and Overnight Brain Recovery | 1 | GlobeNewswire (USA) | ||
| 06.05. | BioAdaptives Inc.: BioAdaptives, Inc. Launches MyndRenew to Complete the 24-Hour Brain Performance Cycle | 218 | GlobeNewswire (Europe) | LAS VEGAS, May 06, 2026 (GLOBE NEWSWIRE) -- via IBN - More than 1 in 3 American adults report insufficient sleep - a deficit that research increasingly links to measurable declines in next-day cognitive... ► Artikel lesen | |
| 28.04. | BioAdaptives Inc.: BioAdaptives introduces MyndSystem, an integrated Neuro-Performance & Repair system for day and night | 1 | GlobeNewswire (USA) | ||
| 14.04. | BIOADAPTIVES, INC. - 10-K, Annual Report | - | SEC Filings | ||
| 31.03. | BIOADAPTIVES, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
| 07.10.25 | BioAdaptives Inc.: BioAdaptives Announces Commercial Launch of MyndMed Following Successful Pilot Testing | 254 | GlobeNewswire (Europe) | LAS VEGAS, Oct. 07, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT) today announced the commercial availability of MyndMed, a next-generation cognitive-support dietary supplement... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 13,730 | 0,00 % | Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy | ||
| BIONTECH | 88,30 | +0,11 % | Kurssprünge und Kaufempfehlungen! Neues Kursziel bei Almonty! CTS Eventim und BioNTech melden sich zurück! | Was für ein Comeback! Im August ist die Aktie von Almonty um über 50 % explodiert! Dafür gibt es gute Gründe. Wolfram ist im Westen knapp und wird von der hochfahrenden Waffenproduktion in den USA dringend... ► Artikel lesen | |
| QIAGEN | 37,590 | -0,42 % | QIAGEN ernennt Jonathan M. Pratt zum Vorstandschef | Bad Marienberg (www.anleihencheck.de) - QIAGEN N.V. ((ISIN NL0015001WM6/ WKN A41HBE; NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Ernennung von Jonathan M. Pratt zum Vorstandsvorsitzenden... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 23,780 | 0,00 % | Here's Why You Should Add ARQT Stock to Your Portfolio Now | ||
| HARMONY BIOSCIENCES | 39,210 | 0,00 % | Wolfe Research initiates Harmony Biosciences stock at Outperform | ||
| ERASCA | 18,040 | +0,06 % | Erasca, Inc. - 8-K, Current Report | ||
| APOGEE THERAPEUTICS | 134,97 | 0,00 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,670 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| MODERNA | 119,06 | -0,03 % | Milliardenmarkt Krebs: Moderna und Merck läuten die nächste Biotech-Ära ein | Ein Durchbruch in der Krebsforschung sorgt für Euphorie an der Börse. Moderna und Merck feiern einen Studienerfolg. Jetzt hoffen Anleger auf die nächste große Biotech-Rallye und neue Milliardenmärkte.... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 345,01 | +0,08 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| RELAY THERAPEUTICS | 18,760 | -0,05 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 78,08 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| VERA THERAPEUTICS | 34,210 | +0,06 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,370 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,770 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6- month interim analysis and FDA feedback on the BLA... ► Artikel lesen |
BIOADAPTIVES INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOADAPTIVES INC finden Sie auf Wallstreet Online.